Roche has decided to stop developing satralizumab for bone health in Duchenne muscular dystrophy, the company announced.

"Fast Track designation is an important regulatory milestone for PBGENE-DMD and reflects the significant unmet need in DMD," said Michael Amoroso, Chief Executive Officer of Precision BioSciences. "We ...

New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history -- Data expand ...

– U.S. FDA Study May Proceed notification enables initiation of clinical trial site activation for the FUNCTION-DMD Phase 1/2 clinical study in patients with Duchenne muscular dystrophy (DMD) – – ...

Durham-based Precision BioSciences, a gene-editing company, has received regulatory clearance to begin a clinical study of its potential treatment for Duchenne muscular dystrophy (DMD), a rare ...

Delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), showed high dystrophin expression and a favorable safety profile in young patients. Based on western blot testing, ...

New pharmacokinetic and cardiac biomarker data further demonstrate ifetroban's potential to protect the heart and reduce cardiac damage in DMD patients "Seeing these promising results validates our ...

Ifetroban significantly improved LVEF in DMD patients, showing a 5.4% improvement compared with propensity-matched natural history controls, with high-dose treatment yielding the most benefit. The ...

Duchenne muscular dystrophy (DMD) drug Emflaza had a controversial past under its previous owner, but its current captain, PTC Therapeutics, is forging ahead—and a new FDA approval could help. The FDA ...